Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2003) 6 P36

SFE2003 Poster Presentations Endocrine tumours and neoplasia (13 abstracts)

Macroprolactinomas in men: long-term efficacy of bromocriptine treatment

A Chattopadhyay , A Bhansali & RJ Dash


Department of Endocrinology, Postgraduate Institute of MedicalEducation and Research (PGIMER), Chandigarh, India.


Gender-specific differences in tumor size at clinical presentation and possible differences in tumor biology make it important to determine treatment outcomes of male patients with bromocriptine [BRC]. We retrospectively analysed treatment response to bromocriptine in 29 male patients with macroprolactinoma (15) and giant macroprolactinoma (14). The duration of treatment was 6-96 months (mean 22.7). Clinical features at presentation included headache (21, 72.4%), visual field defects (20, 69%), libido-potency failure (18, 62.1%), pituitary apoplexy (5, 17 %), primary infertility (5, 17%), gynaecomastia / galactorrhoea (4, 12%). Pretreatment serum prolactin (PRL) ranged between 124 and 29,200 nanogram per mililitre and tumour volume, between 5.4 and 252 cm3.

In 26 patients, PRL decreased 96% of the pretreatment value; PRL was normalised (<16 nanogram per mililitre) in 12 patients (41%). Tumour shrinkage at final follow-up was > 50% in 22 patients (74.8%); with near complete disappearance in 5, > 95% in 7, and >50% in 10 patients. Tumour volume reduction in both giant prolactinoma (P= 0.005) and macroprolactinoma (P= 0.02) was significant.An improvement of field defect was noted in 8 out of 20 patients (40%). Nine patients with secondary hypoadrenalism, 7 with secondary hypothyroidism and 7 with hypogonadism needed substitutive therapy. Trans-sphenoidal surgery was performed in 9 patients (CSF leakage related to BRC in 2, increasing prolactin despite BRC in 3, pituitary apoplexy in 1 and unable to afford the cost of long term BRC in 3). Among the five patients presenting with primary infertility, 2 had normalised PRL, improvement in sperm count and had a child.

These data suggest that, in male macro-and giant prolactinomas, bromocriptine represents a first-line therapy effective in reducing PRL, determining tumour shrinkage, preserving/ restoring vision and pituitary function.

Volume 6

194th Meeting of the Society for Endocrinology and Society for Endocrinology joint with Diabetes UK Endocrinology and Diabetes Day

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.